evidence table

Choline Cognition Randomized Trial Evidence Table

Name: Choline Cognition Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Choline Cognition Randomized Trial, generated from 4 reusable source documents in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Choline Cognition Randomized Trial	1 The first 1000 days of life—from conception and pregnancy through the first 2 years—represent a period often described as a “window of opportunity” to promote better developmental outcomes, but it can also be considered a “window of susceptibility,” during which adverse epigenetic influences, an increased risk of disease development and nutritional deficiency may occur [].	3	Sollena Laura Maria (2026)	DHA: Nutritional Programming During the First 1000 Days of Life
Choline Cognition Randomized Trial	Eligible studies included randomized controlled trials, follow-up studies, systematic reviews and meta-analyses, and observational studies reporting clinical, developmental, or biochemical outcomes associated with DHA exposure.	3	Sollena Laura Maria (2026)	DHA: Nutritional Programming During the First 1000 Days of Life
Choline Cognition Randomized Trial	Level of evidence (LOE) was qualitatively assigned according to GRADE, used as a conceptual framework rather than a formal systematic grading approach.	3	Sollena Laura Maria (2026)	DHA: Nutritional Programming During the First 1000 Days of Life
Choline Cognition Randomized Trial	2 The essential role of nutrition on brain development during the first 1000 days is widely recognized [].	3	Sollena Laura Maria (2026)	DHA: Nutritional Programming During the First 1000 Days of Life
Choline Cognition Randomized Trial	This review synthesizes current evidence on the effects of both plant- and animal-derived foods on cognitive outcomes from early development through older adulthood.	4	Hardaway C (2026)	Brain Foods: A Narrative Review of Food Items and Their Impact on Cognition over the Life Course.
Choline Cognition Randomized Trial	Evidence was evaluated across life stages, considering nutrient bioavailability, dietary patterns, and the interplay between structural, socioeconomic, and environmental factors that influence access to these foods.	4	Hardaway C (2026)	Brain Foods: A Narrative Review of Food Items and Their Impact on Cognition over the Life Course.
Choline Cognition Randomized Trial	In early childhood, eggs, meat, and nuts were linked to improved neurodevelopment and reductions in developmental delays, while evidence for seafood and dairy was more mixed.	4	Hardaway C (2026)	Brain Foods: A Narrative Review of Food Items and Their Impact on Cognition over the Life Course.
Choline Cognition Randomized Trial	Background/Objectives : Cognitive function is fundamental to daily life, and nutrition is a key modifiable determinant of brain health across the lifespan.	4	Hardaway C (2026)	Brain Foods: A Narrative Review of Food Items and Their Impact on Cognition over the Life Course.
Choline Cognition Randomized Trial	This narrative review summarizes current preclinical and clinical evidence regarding the mechanistic and clinical relevance of L-α-GPC in neurodegenerative disorders associated with cognitive impairment.	4	Putri VA (2026)	L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders.
Choline Cognition Randomized Trial	In animal models, L-α-GPC has been associated with improved cognitive performance, reduced neuroinflammation, and attenuation of amyloid-β and tau-related pathological features.	4	Putri VA (2026)	L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders.
Choline Cognition Randomized Trial	However, the interpretation of these findings should be cautious because the available evidence remains heterogeneous, with notable variability in study design, dosage regimens, treatment duration, and outcome measures.	4	Putri VA (2026)	L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders.
Choline Cognition Randomized Trial	Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and vascular dementia are characterized by progressive neuronal loss, synaptic dysfunction, and cognitive decline.	4	Putri VA (2026)	L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders.